drugset / Trial / NCT05407285

A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users

NCT05407285

Phase 1/2 Completed 70 enrolled University of Montreal Hospital Centre (CHUM)
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purposes of this study are 1) to determine if the administration of different low doses of oral CBD (20 mg, 50 mg, 100 mg and 200 mg) result in detectable subjective pleasant drug effect compared to placebo and 2) to qualitatively explore whether low dose of oral CBD is associated with effects that are not detected with the available research tools.

Timeline

Start
2022-07-22
Primary completion
2023-11-14
Completion
2023-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 20 mg Oral
Subject Cannabidiol Other / unclassified 50 mg Oral
Subject Cannabidiol Other / unclassified 100 mg Oral
Subject Cannabidiol Other / unclassified 200 mg Oral

Indications